慢性肾脏病患者脑动脉造影与神经血管内治疗的安全性
回顾性分析两家学术医疗中心4年内接受常规脑动脉造影及神经血管内干预的185例高危患者,以术后48-72小时血肌酐绝对升高0.5 mg/dL或较基线升高≥25%定义对比剂肾病,仅1/184(0.54%)发生对比剂肾病,该例为5期慢性肾脏病且合并多种其他危险因素。
要点
- 慢性肾脏病3-5期患者行脑动脉造影或神经血管内治疗后对比剂肾病发生率很低(1/184,0.54%)。
- 高危定义为术前估算肾小球滤过率<60 mL/min,对应慢性肾脏病3-5期。
- 对比剂肾病判定为术后48-72小时血肌酐绝对升高0.5 mg/dL或较基线升高≥25%。
核心结论
- 在传统上被视为神经血管内操作高危的慢性肾脏病患者中,观察到的肾损伤发生率很低(1/184,0.54%),多种因素可能与该人群对比剂肾病风险降低有关。
研究设计与样本
- 回顾性分析两家学术医疗中心4年内接受常规脑动脉造影和神经血管内干预的高危患者,高危定义为术前估算肾小球滤过率<60 mL/min(慢性肾脏病3-5期),共识别185例,其中184例纳入对比剂肾病分析。
诊断标准与关键数值
- 对比剂肾病定义为暴露于对比剂后48-72小时血肌酐绝对升高0.5 mg/dL或较基线值升高≥25%,并排除其他肾损伤原因;高危患者为术前估算肾小球滤过率<60 mL/min,对应慢性肾脏病3-5期。
临床应用与阅片要点
- 本研究中心的做法是对接受神经血管内操作的患者按术前估算肾小球滤过率<60 mL/min识别高危人群,并在术后48-72小时监测血肌酐以判定对比剂肾病。
局限性
- 原文为回顾性分析。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: Contrast-induced nephropathy is a common clinical concern in patients undergoing neuroendovascular procedures, especially in those with pre-existent kidney disease. We aimed to define the incidence of contrast-induced nephropathy in these high-risk patients in our practice.
METHODS: We analyzed data retrospectively from patients undergoing neuroendovascular procedures at two academic medical centers over a 4-year period. Contrast-induced nephropathy was determined by an absolute increase in serum creatinine of 0.5 mg/dL or a rise from its baseline value by ≥ 25%, at 48-72 h after exposure to contrast agent after excluding other causes of renal impairment. High-risk patients were identified as those with pre-procedural estimated glomerular filtration rate < 60 mL/min irrespective of creatinine level, corresponding to stages 3-5 of chronic kidney disease.
RESULTS: One hundred eighty-five high-risk patients undergoing conventional cerebral angiography and neuroendovascular interventions were identified. Only 1 out of 184 (0.54%) high-risk patients developed contrast-induced nephropathy. That one patient had stage 5 chronic kidney disease and multiple other risk factors.
CONCLUSION: We have observed a very low rate of renal injury in patients with chronic kidney disease, traditionally considered high risk for neuroendovascular procedures. Multiple factors may be responsible in the risk reduction of contrast-induced nephropathy in this patient population.
引用
- Kim J, Male S, Jagadeesan BD, et al. Safety of cerebral angiography and neuroendovascular therapy in patients with chronic kidney disease. Neuroradiology. 2018. PMID: 29497786. doi:10.1007/s00234-018-1996-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。